Clinical Trial Update: ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 trial results for ABX464 in patients with moderate to severe active ulcerative colitis have been posted. The update covers efficacy and safety findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• ABX464 (ABX464)

Snippet

Sponsor: Abivax S.A. | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED | Results posted: 2023-02-08